Episode Summary
Executive Summary: Scott Galloway interviews Ronan Levy, co-founder of Field Trip Health, about the emerging psychedelic medicine industry. They cover the science and business of ketamine, MDMA, and psilocybin; the importance of set, setting, and integration; the risks of bad experiences and overmedicalization; and how the sector may evolve into both clinical and wellness models. Levy argues psychedelics may transform mental health and society.
Main Topics: State of the psychedelic renaissance (Priority: 5/5): Levy frames the current moment as the start of a new psychedelic era, driven by research from major institutions and growing clinical access, with FDA/Health Canada approvals expected for MDMA and psilocybin in the coming years. Field Trip’s integrated business model (Priority: 5/5): Field Trip combines clinic infrastructure with drug development, aiming to deliver psychedelic-assisted therapy at scale while also creating shorter-duration molecules that preserve benefits but reduce cost and session length. Comparing ketamine, MDMA, and psilocybin (Priority: 5/5): The conversation distinguishes current and emerging uses: ketamine for depression/suicidality, MDMA for PTSD, and psilocybin for depression and potentially broader indications, while noting research is still indication-specific. Therapeutic model: set, setting, and integration (Priority: 5/5): Levy emphasizes that outcomes depend not just on the molecule, but on preparation, environment, therapist support, and post-session integration to translate experiences into lasting behavior change. Risks, side effects, and safety (Priority: 4/5): They discuss bad trips, trauma risk, adverse events, addiction potential, and drug purity concerns. Levy argues proper clinical support dramatically reduces risk and that ketamine is especially safe physically. Capitalism, regulation, and industry structure (Priority: 4/5): A listener asks whether for-profit models can responsibly govern psychedelics. Levy argues market incentives can coexist with regulation and may self-correct as psychedelic experiences make people more open and less ruthlessly profit-driven. Wellness, access, and post-therapy practices (Priority: 4/5): The episode ends on how to retain psychedelic insights through gratitude, meditation, journaling, and sensory cues, suggesting psychedelics may become part of ongoing mental hygiene rather than a one-time intervention.
Key Arguments: The psychedelic sector is entering a renaissance after decades of dormancy, supported by modern research and near-term approvals. Psychedelic medicine is fundamentally experiential; outcomes depend on preparation, environment, and therapist-guided integration as much as on the drug. Field Trip’s clinic network is designed to scale safe, supervised psychedelic-assisted therapy rather than simple drug distribution. A shorter-acting psilocybin-like molecule could materially improve accessibility by cutting time, space, and clinician costs roughly in half. Ketamine currently offers one of the best legally available treatments for depression in Canada and the US, while MDMA and psilocybin are likely next. The clinical literature suggests strong efficacy: ketamine can produce long symptom relief; MDMA shows high PTSD response/cure rates; psilocybin may have durable antidepressant effects. Many supposed category boundaries between ketamine, MDMA, and psilocybin are practical artifacts of research design, not necessarily limits of therapeutic value. Psychedelic-assisted therapy should be used for both problem-solving (depression, PTSD, trauma) and enhancement (resilience, self-understanding, creativity). The main harms come from poor context, impure drugs, or lack of support—not from the molecules alone, especially in supervised settings. The industry may split into medical and wellness tracks, similar to cannabis, with insurance coverage likely driving the most scalable access. Psychedelics could have a broad cultural impact by shifting people toward empathy, openness, and different life decisions. Integration practices such as gratitude, meditation, and sensory cues help preserve the afterglow and convert insight into sustained change.
Data Points: Approval timeline: 18 months to 4 years - Levy says MDMA-assisted therapy and psilocybin-assisted therapy may be approved by the FDA and Health Canada within this window. Field Trip clinic cities: 8 listed locations - Toronto, New York, LA, Chicago, Vancouver, Atlanta, Houston, and expanding. Psilocybin therapy duration: 4 to 6 hours - Levy describes the typical length of a psilocybin experience. MDMA therapy duration: 8 to 10 hours - Levy describes the typical length of an MDMA-assisted therapy session. Field Trip molecule duration target: About half the duration of psilocybin - Field Trip is developing a molecule similar to psilocybin but with shorter treatment time. Ketamine relief duration: 120 days or more - Levy says some depression patients in clinics experience relief for this long after a couple of sessions. MAPS PTSD trial outcome: 70% cure rate - Levy cites MAPS phase 3 results for MDMA-assisted therapy in PTSD. Chronic PTSD baseline: 7 years on average - Average chronic severe PTSD duration among trial participants described by Levy. Current PTSD treatment improvement: 30% symptom improvement - Levy contrasts current treatment expectations with MDMA trial outcomes. Depression resource use: Up to 40% more conventional medical resources - He says people with major depression consume significantly more healthcare resources. People on the planet with trauma: Roughly 10 billion - Levy argues trauma is nearly universal, supporting large long-term demand. Current medical access model: Treatment-resistant depression focus - Field Trip initially targeted treatment-resistant conditions but is widening eligibility within the clinical paradigm. MDMA recreational caution: Cut with cocaine, amphetamines, or fentanyl - Levy says contamination/purity is the biggest recreational MDMA risk.
Pivotal Quotes: "We are in the midst, right? Right at the beginning, actually, of a psychedelic renaissance." — Ronan Levy: He summarizes the current state of the emerging psychedelics industry. "It’s not just your brain happening, that there’s a whole bunch of lifestyle aspects that go along with enhancing one’s mental health." — Ronan Levy: He explains why integration and behavioral change are central to psychedelic therapy. "This is not taking LSD and going to a concert. This is working with these drugs in a set-in setting with a therapist to really make the most of the experience." — Ronan Levy: He distinguishes clinical psychedelic therapy from recreational use.
Implications: The episode suggests psychedelics may become mainstream mental-health tools, split into medical and wellness markets. Success will depend on regulation, therapist-led care, and integration, with major implications for psychiatry, insurance, and consumer behavior.